Selank (TP-7 / Tuftsin Analog) Evidence Grade: A-
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunopeptide tuftsin with a stabilizing Pro-Gly-Pro C-terminal extension. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Semax, Selank is approved in Russia as a prescription anxiolytic and nootropic agent. It produces anti-anxiety effects comparable to benzodiazepines without sedation, cognitive impairment, or addiction potential.
Selank's unique pharmacological profile combines anxiolytic, nootropic, and immunomodulatory effects in a single compound, reflecting its dual heritage from the tuftsin immunopeptide parent and the neurotropic design principles applied during development. It modulates GABAergic, serotonergic, and dopaminergic neurotransmission while simultaneously enhancing innate immune function through phagocyte activation and cytokine regulation.
Table of Contents
Overview & Introduction
Selank was developed using the same pharmacological design strategy as Semax: take a biologically active endogenous peptide fragment and add a Pro-Gly-Pro C-terminal extension to increase enzymatic stability and extend biological half-life. For Selank, the starting point was tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide naturally produced by enzymatic cleavage of immunoglobulin G (IgG) in the spleen.
Tuftsin itself is an endogenous immunostimulant that activates phagocytosis, natural killer cell activity, and monocyte/macrophage function. The Pro-Gly-Pro extension not only stabilized the molecule but unexpectedly conferred potent anxiolytic and nootropic properties beyond the parent peptide's immune effects. This serendipitous discovery led to Selank's development as a dual-action compound with both neurotropic and immunotropic activities.
The anxiolytic mechanism involves modulation of GABA-A receptor allosteric sites, enhancement of serotonergic neurotransmission, and regulation of enkephalin gene expression. Unlike benzodiazepines, which directly potentiate GABA-A receptor chloride channel activity, Selank appears to increase GABA-A receptor sensitivity to endogenous GABA. This indirect modulation produces anxiolysis without the sedation, ataxia, cognitive impairment, or dependence associated with direct GABA-A agonism.
Selank received regulatory approval in Russia and has been used clinically since 2009. It is available as a 0.15% nasal spray indicated for generalized anxiety disorder, neurasthenia, and as an adjunctive treatment for anxiety-related cognitive impairment. The compound's simultaneous anxiolytic and cognitive-enhancing properties make it particularly suitable for anxiety disorders where cognitive symptoms (impaired concentration, memory difficulties) are prominent.
History & Discovery
Tuftsin characterization. Tuftsin was established as an endogenous immunostimulatory tetrapeptide derived from IgG. Its role in phagocyte activation and innate immunity was well characterized.
Selank synthesis. Scientists at the Institute of Molecular Genetics added the Pro-Gly-Pro extension to tuftsin, creating TP-7 (Selank). The stabilized analog demonstrated unexpectedly potent anxiolytic and nootropic effects in animal behavioral models.
Clinical development. Extensive preclinical and clinical studies characterized Selank's anxiolytic efficacy, GABAergic mechanism, immunomodulatory effects, and safety profile. Phase II/III clinical trials compared Selank to benzodiazepines and placebo.
Russian regulatory approval. Selank received approval in Russia as a 0.15% intranasal solution for anxiety and neurasthenia. Made available by prescription.
International research. Selank gained global research attention for its unique non-sedating anxiolytic profile. Studies expanded into antiviral effects, gene expression modulation, and PTSD research.
Mechanism of Action
Selank enhances GABA-A receptor sensitivity to endogenous GABA through allosteric modulation. Unlike benzodiazepines, which bind directly to the benzodiazepine site on GABA-A, Selank appears to modulate receptor conformation to increase GABA binding affinity. This produces anxiolysis without excessive inhibition, preserving normal cognitive function and motor coordination. Studies show Selank increases benzodiazepine binding site density in the hippocampus.
Selank modulates serotonin (5-HT) metabolism and receptor sensitivity, particularly in limbic structures involved in anxiety processing (amygdala, hippocampus, prefrontal cortex). It influences the balance between serotonin synthesis, release, and reuptake, contributing to mood stabilization and anxiolysis. This serotonergic mechanism complements the GABAergic effects and may account for the compound's antidepressant-like properties.
Selank upregulates proenkephalin gene expression in the hippocampus, increasing endogenous enkephalin (opioid peptide) levels. Enkephalins modulate pain perception, stress responses, and emotional processing through delta-opioid receptors. This endogenous opioid modulation contributes to stress resilience and emotional regulation without producing opioid-like euphoria or dependence.
Selank retains and enhances the immunostimulatory properties of its parent peptide tuftsin. It activates phagocytosis, increases natural killer cell activity, modulates cytokine production (IL-6, TNF-alpha regulation), and influences antiviral defense pathways. In vitro studies have demonstrated antiviral activity against influenza A virus. This immune modulation is unique among anxiolytic compounds.
Research Applications
Generalized Anxiety Disorder
Primary clinical indication. Selank's non-sedating anxiolytic profile makes it suitable for daytime anxiety management where cognitive function must be preserved.
Cognitive Enhancement Under Stress
Selank improves cognitive performance (attention, memory, processing speed) specifically under stress conditions. Its dual anxiolytic-nootropic profile restores stress-impaired cognition.
Immune System Research
The tuftsin-derived immune effects make Selank unique for studying the neuro-immune interface. It is investigated for combined anxiolytic and immunomodulatory applications.
Antiviral Research
Selank has demonstrated in vitro antiviral activity, particularly against influenza A. The mechanism involves upregulation of interferon-related gene expression and innate immune pathway activation.
Clinical Evidence
Anxiolytic Efficacy in GAD
Zozulia et al. (2008) conducted a controlled clinical trial of Selank (0.15% intranasal) in patients with generalized anxiety disorder. Selank produced statistically significant reductions in anxiety scores comparable to phenazepam (a benzodiazepine), with preserved cognitive function and no sedation. The study established Selank as a viable non-benzodiazepine anxiolytic.
PMID: 18577976
GABA System Modulation
Seredenin et al. (1998) characterized Selank's GABAergic mechanism in rodent models. The study demonstrated that Selank increases benzodiazepine receptor binding in hippocampal membranes and enhances the inhibitory effects of GABA on neuronal firing. The anxiolytic effect was partially blocked by flumazenil (a benzodiazepine antagonist), confirming GABAergic involvement.
PMID: 9830143
Gene Expression and Enkephalin Regulation
Kost et al. (2001) studied Selank's effects on enkephalin gene expression in the hippocampus. Treatment significantly increased proenkephalin mRNA levels, establishing an endogenous opioid peptide mechanism that contributes to Selank's anxiolytic and stress-modulating effects without producing opioid dependence.
PMID: 11515319
Antiviral Activity
Ershov et al. (2009) demonstrated that Selank stimulates expression of interferon-related genes and enhances innate antiviral defense pathways. In vitro, Selank inhibited influenza A virus replication. This dual neuro-immune activity is unique among anxiolytic compounds and reflects the tuftsin heritage of the peptide.
PMID: 19240833
Dosing Protocols (Research Context)
Note: Selank is approved in Russia but not FDA/EMA-approved.
| Form | Dose | Frequency |
|---|---|---|
| 0.15% Nasal Solution | 250-500 mcg/day (2-3 drops per nostril) | 3 times daily |
| Subcutaneous Injection | 250-750 mcg | 1-2 times daily |
Standard protocols run 14-21 days. Cycles can be repeated after 1-2 week intervals. No tapering required upon discontinuation.
Administration & Reconstitution
Nasal Spray (Primary)
Pre-mixed 0.15% solution. Administer drops intranasally, alternating nostrils. Provides rapid CNS access via olfactory pathways.
Injectable
| Vial | BAC Water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
- Reconstitute gently; inject subcutaneously
- Intranasal route preferred for anxiolytic effects
Side Effects & Safety Profile
Selank has an outstanding safety profile with no significant adverse events in 15+ years of clinical use in Russia.
Rare/Mild
- Mild nasal irritation
- Occasional fatigue (uncommon)
Key Safety Features
- No sedation
- No addiction or dependence
- No withdrawal or rebound anxiety
- No cognitive impairment
- No motor coordination effects
Stacking & Combinations
Selank + Semax
The flagship Russian nootropic combination. Semax provides BDNF-driven cognitive enhancement while Selank delivers anxiolysis and stress resilience. Together they optimize cognitive performance under pressure.
Selank + BPC-157
For gut-brain axis research: Selank's anxiolytic/serotonergic effects complement BPC-157's gut healing and dopaminergic modulation. Both compounds influence the gut-brain connection through different mechanisms.
Selank + Thymosin Alpha-1
For combined immune and neurological support: Selank provides tuftsin-derived immune activation plus anxiolysis, while Thymosin Alpha-1 delivers T-cell immune enhancement.
Storage & Stability
| Form | Conditions | Duration |
|---|---|---|
| Nasal Solution (sealed) | Refrigerated | Until expiry |
| Nasal Solution (opened) | Refrigerated | 30 days |
| Lyophilized | Refrigerated | 24+ months |
| Reconstituted | Refrigerated | 21 days |
Regulatory Status
- Russia: Approved (2009) as prescription anxiolytic and nootropic. Available as 0.15% nasal solution.
- United States: Not FDA-approved. Research peptide.
- EU: Not EMA-approved.
- WADA: Not currently prohibited.
Frequently Asked Questions
How does Selank compare to benzodiazepines?
What is tuftsin and why is Selank based on it?
Is Selank addictive?
References
- Zozulia AA, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank." Zh Nevrol Psikhiatr. 2008;108(4):38-48. PMID: 18577976
- Seredenin SB, et al. "Selank and the benzodiazepine receptor." Bull Exp Biol Med. 1998;126(11):1094-1097. PMID: 9830143
- Kost NV, et al. "Effect of Selank on enkephalin gene expression." Bull Exp Biol Med. 2001;132(5):1025-1027. PMID: 11515319
- Ershov FI, et al. "Antiviral activity of Selank." Vopr Virusol. 2009;54(5):19-24. PMID: 19240833
Related Pages
Concise compound overview
Step-by-step protocol
Nootropic combination partner
Immune support partner
Medical Disclaimer: This article is for educational and research purposes only. Selank is not FDA-approved. Consult a healthcare professional. See our full Medical Disclaimer.
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.